Rite Aid management issued an unusual plea for shareholders to vote in favor of its merger with Albertsons amid opposition by some investors who’ve been trying to derail the deal.
Category: Forbes
Individuality In Healthcare, Part 2 — Does It Expose An Individual’s Vulnerabilities?
Individuality has moved to the center of healthcare transformation. It is redefining the ways we serve patients and our communities. How healthcare serves the unique needs of individuals, by being more inclusive to their vulnerabilities will define t…
As Numbers Swell, Nurse Practitioners Launch National Campaign
The American Association of Nurse Practitioners is launching a $2 million education and public awareness campaign as numbers of NPs swell to a quarter million.
Big Business Coalitions To Form National Value-Based Payment Network
The National Alliance of Healthcare Purchaser Coalitions and Remedy Partners are teaming up to accelerate employer adoption of bundled payments, a form of value-based care.
Big Pharma Rises To The Ebola Challenge
“If you have technology that can help fight the most deadly virus in the world, you can’t stand back and not do this.”
Osso VR Surgical Training Makes Push Into Med Schools
Osso VR’s realistic surgical simulations are being used by med schools to train new surgeons.
Legal Finance Companies Descend On Florida Convention To Build Relationships With Trial Lawyers
When Florida trial lawyers gathered for their annual convention last week, another industry set up shop in the convention hall.
Sticker Shock: The Real Cost Of America’s 10 Most Expensive Drugs
The high price of pharmaceuticals have become a constant topic of discussion in the U.S. although very few consumers ever pay out-of-pocket prices thanks to insurance. But in the case that an individual had to pay list price, the following 10 drugs are…
FDA Approves First-Ever Medication Containing Ingredient Directly Purified From Cannabis
A cannabis-based drug for two childhood epilepsy syndromes has become the first drug containing a purified cannabis compound to gain FDA approval.
Are Orphan Drugs Getting Too Much Attention By Payers And Policymakers?
Success of the Orphan Drug Act has brought with it pushback from payers, policymakers, and legislators. Pushback may be warranted in some instances. But, a case-by-case approach examining the value of orphan products, independent of their orphan status…
